Media coverage about Voyager Therapeutics (NASDAQ:VYGR) has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Voyager Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.0829405524897 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- MRI Interventions posts narrower 1Q loss, announces tie-up with Voyager Therapeutics (proactiveinvestors.com)
- Voyager: Running Into Key Presentation (seekingalpha.com)
- MRI Interventions Announces Strategic Agreement with Voyager Therapeutics for Neurosurgical Device Service, Supply and Development (finance.yahoo.com)
- Reader Inquiry: When Will Voyager Therapeutics Rebound? (seekingalpha.com)
- Voyager Therapeutics (VYGR) Stock Rating Reaffirmed by BTIG Research (americanbankingnews.com)
Voyager Therapeutics stock traded up $0.85 during trading hours on Thursday, hitting $21.10. The stock had a trading volume of 6,677 shares, compared to its average volume of 419,904. The company has a market capitalization of $664.20 million, a PE ratio of -7.86 and a beta of 2.98. Voyager Therapeutics has a one year low of $20.70 and a one year high of $21.45.
Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Thursday, May 10th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.52). The firm had revenue of $0.94 million during the quarter, compared to the consensus estimate of $4.00 million. Voyager Therapeutics had a negative net margin of 768.99% and a negative return on equity of 69.92%. equities research analysts forecast that Voyager Therapeutics will post -2.75 EPS for the current year.
Several brokerages recently weighed in on VYGR. BTIG Research restated a “buy” rating on shares of Voyager Therapeutics in a research report on Sunday. BidaskClub upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 4th. Canaccord Genuity set a $35.00 price objective on Voyager Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 10th. Wedbush upgraded Voyager Therapeutics from a “neutral” rating to an “outperform” rating in a research report on Friday, May 11th. Finally, ValuEngine upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Voyager Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $29.73.
In other Voyager Therapeutics news, insider Dinah Ph.D. Sah sold 15,623 shares of the stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $30.00, for a total value of $468,690.00. Following the completion of the transaction, the insider now directly owns 140,872 shares in the company, valued at $4,226,160. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bernard Ravina sold 2,451 shares of the stock in a transaction dated Tuesday, April 10th. The shares were sold at an average price of $18.38, for a total value of $45,049.38. The disclosure for this sale can be found here. Insiders sold 64,457 shares of company stock valued at $1,529,552 over the last quarter. Corporate insiders own 8.00% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.